MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020005795
Abstract: Multiple myeloma (MM) remains largely incurable despite significant advances in bio- and chemotherapy. The major problem in MM management is development of drug resistance. Macrophage migration inhibitory factor (MIF) expression was significantly higher in purified… read more here.
Keywords: biomarker therapeutic; myeloma; mif biomarker; resistance ... See more keywords